A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy

In brief

The main purpose of this study is to assess the effect of itraconazole and rifampin on how fast selpercatinib gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study is conducted in two parts and it will last up to 54 days (part 1) and 59 days (part 2), respectively, inclusive of screening period.

Key facts

Study ID
NCT05338489
Run by
Eli Lilly and Company
People needed
24
Starts
2018-05-11
Expected to finish
2018-08-22
Last updated by the study team
2025-09-19

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.